Literature DB >> 14681308

The restriction site mutation (RSM) method: clinical applications.

G J S Jenkins1.   

Abstract

The restriction site mutation (RSM) method has been developed over the past 13 years as a sensitive mutation test which can detect mutations in restriction sites in any gene. Due to the fact that 5/8 of the main mutation hotspots in the TP53 gene fall within restriction sites, RSM can analyse them for the presence of rare mutations (1 mutation in 10000 non-mutated copies). After validating the usefulness of RSM in detecting mutagen-induced mutations, we recently turned our attention to looking for TP53 mutations in pre-malignant tissue. We show here that RSM can detect early TP53 mutations in pre-malignant tissue of the oesophagus, stomach, colon and bladder. We can also use these clinical mutation data to speculate as to the causative mutagens involved in these cancer conditions. We here use an example of mutations detected in gastric tissue and those induced in vitro by hydrogen peroxide.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14681308     DOI: 10.1093/mutage/geg037

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  3 in total

Review 1.  Pre-PCR Mutation-Enrichment Methods for Liquid Biopsy Applications.

Authors:  Farzaneh Darbeheshti; Fangyan Yu; G Mike Makrigiorgos
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

2.  Editing of hnRNP K protein mRNA in colorectal adenocarcinoma and surrounding mucosa.

Authors:  K Klimek-Tomczak; M Mikula; A Dzwonek; A Paziewska; J Karczmarski; E Hennig; J M Bujnicki; P Bragoszewski; O Denisenko; K Bomsztyk; J Ostrowski
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640

3.  High-throughput detection of induced mutations and natural variation using KeyPoint technology.

Authors:  Diana Rigola; Jan van Oeveren; Antoine Janssen; Anita Bonné; Harrie Schneiders; Hein J A van der Poel; Nathalie J van Orsouw; René C J Hogers; Michiel T J de Both; Michiel J T van Eijk
Journal:  PLoS One       Date:  2009-03-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.